Autopsy report · NCT00954005

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

“Predefined termination criterion of \> 10 patients without CR or PR was matched.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 years 7 months after it had already started.
• Ran for about 9 years 5 months before it stopped.
• 56 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

German Low Grade Lymphoma Study Group

Sponsor type

University, hospital or other

Conditions

Indolent Lymphoma

Interventions

Therapy with Rituximab, Gemcitabine and Oxaliplatin

Participants

56

Sites

1

Countries

Germany

Trials that died the same way

• Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
  “Early termination (regarding the follow-up of the patients). The required sample size was reached, and the primary endpoint was met.” (68% match in meaning)
• A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
  “no more patients corresponding to the criteriae” (60% match in meaning)
• Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
  “Standard of care evolved during the timeframe of the study and had critical impact on recruitment. Early termination was not based on safety reasons but due to the reasons mentoined above. The ongoing patients were completed.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.